Advisory Meeting on Tenofovir/FTC for PrEP, and a Proposed "Niche" for its Use
FEATURE
In his blog HIV and ID Observations , Dr. Paul Sax describes one scenario in which pre-exposure prophylaxis "makes a whole lot of sense."
ART Reduces TB Risk, Even in High-Income Countries
SUMMARY AND COMMENT
However, the benefit is not seen in patients who start ART at very low CD4-cell counts.
Reviewing:
The HIV-CAUSAL Collaboration., Clin Infect Dis 2012 May 1; 54:1364
Dolutegravir Holds Promise
SUMMARY AND COMMENT
In a 48-week, phase II study, this investigational integrase inhibitor was as effective as efavirenz and better tolerated.
Reviewing:
van Lunzen J et al., Lancet Infect Dis 2012 Feb; 12:111
Funding HIV Activities at the State Level: Is There a Better Way?
SUMMARY AND COMMENT
The amount of funding that states receive may not adequately reflect the relative burden of disease they face.
Reviewing:
Mansergh G et al., J Acquir Immune Defic Syndr 2012 Apr 15; 59:516
Premature Aging with HIV Infection: More Evidence
SUMMARY AND COMMENT
May 7, 2012
Nina H. Lin, MD
Despite antiretroviral therapy, young HIV-positive patients had the same monocyte defects as older HIV-negative controls.
Reviewing:
Hearps AC et al., AIDS 2012 Apr 24; 26:843
Frequent Virologic Monitoring Limits NRTI and NNRTI Resistance
SUMMARY AND COMMENT
Ongoing virologic monitoring, along with strict application of criteria for regimen switches, was associated with low rates of resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors, which in turn preserved second-line treatment options.
Reviewing:
Barth RE et al., Antivir Ther 2012 ; 17:377
Wallis CL et al., Antivir Ther 2012 ; 17:313
PrEP in MSM: Enough Bang for the Buck?
SUMMARY AND COMMENT
April 30, 2012
Rochelle P. Walensky, MD, MPH
PrEP may be cost-effective, particularly in high-risk MSM, but many questions remain.
Reviewing:
Juusola JL et al., Ann Intern Med 2012 Apr 17; 156:541
How Well Do MDs Follow HIV Treatment Guidelines?
SUMMARY AND COMMENT
In Australia, they did well in some things, poorly in others.
Reviewing:
Bloch M et al., J Acquir Immune Defic Syndr 2012 Apr 15; 59:478
Do We Really Need Primary Prophylaxis for OIs Anymore?
FEATURE
Maybe not, says Dr. Paul Sax in his blog HIV and ID Observations .
More Evidence that Tenofovir Leads to Bone Loss
SUMMARY AND COMMENT
Patients who switched to tenofovir from AZT experienced significant decreases in BMD. Those who switched to abacavir did not.
Reviewing:
Rasmussen TA et al., PLoS ONE 2012 Mar 29; 7:e32445
